PMID- 19347824
OWN - NLM
STAT- MEDLINE
DCOM- 20090430
LR  - 20110214
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 117
IP  - 1
DP  - 2009 Feb 25
TI  - Reflex UroVysion testing in suspicious urine cytology cases.
PG  - 7-14
LID - 10.1002/cncy.20016 [doi]
AB  - BACKGROUND: UroVysion is a US Food and Drug Administration-approved fluorescence 
      in situ hybridization (FISH) probe set for use in the detection of recurrent 
      urothelial carcinoma and in patients with hematuria. The objective of the current 
      study was to evaluate the usefulness of UroVysion as a reflex test in patients 
      with a suspicious urine cytology diagnosis. The rationale was that a more 
      aggressive workup might be indicated in patients with a suspicious cytology 
      diagnosis and positive UroVysion test. METHODS: The study population included 161 
      urine specimens diagnosed as suspicious over a period of 12 months. The 
      sensitivity, specificity, negative predictive value (NPV), and positive 
      predictive value (NPV) were calculated based on the histologic and cystoscopic 
      correlation. RESULTS: The results using the reporting criteria suggested by the 
      manufacturer demonstrated a sensitivity of 68.3%, a specificity of 39.7%, a PPV 
      of 56.8%, and a NPV of 51.9%. The results using the presence of any cytogenetic 
      abnormality as a positive FISH test demonstrated a sensitivity of 82.9%, a 
      specificity of 21.7%, a PPV of 54.8%, and an NPV of 51.7%. CONCLUSIONS: A 
      negative UroVysion test did not rule out the presence of low-grade or high-grade 
      urothelial carcinoma in urine specimens diagnosed as suspicious. The use of less 
      strict criteria dramatically increased the sensitivity of UroVysion FISH; 
      however, there was a marked decrease in specificity noted. The results in this 
      current study appear to indicate that a more aggressive workup of patients with a 
      suspicious cytology, positive UroVysion result, and negative cystoscopic 
      evaluation is not currently justified.
CI  - (c) 2009 American Cancer Society.
FAU - Ferra, Susana
AU  - Ferra S
AD  - Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York 
      Avenue, New York, NY 10065, USA.
FAU - Denley, Ryan
AU  - Denley R
FAU - Herr, Harry
AU  - Herr H
FAU - Dalbagni, Guido
AU  - Dalbagni G
FAU - Jhanwar, Suresh
AU  - Jhanwar S
FAU - Lin, Oscar
AU  - Lin O
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Transitional Cell/*urine
MH  - Cystoscopy
MH  - False Negative Reactions
MH  - False Positive Reactions
MH  - Female
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence/methods
MH  - Male
MH  - Middle Aged
MH  - Sensitivity and Specificity
MH  - Urinary Bladder Neoplasms/*urine
EDAT- 2009/04/07 09:00
MHDA- 2009/05/01 09:00
CRDT- 2009/04/07 09:00
PHST- 2009/04/07 09:00 [entrez]
PHST- 2009/04/07 09:00 [pubmed]
PHST- 2009/05/01 09:00 [medline]
AID - 10.1002/cncy.20016 [doi]
PST - ppublish
SO  - Cancer. 2009 Feb 25;117(1):7-14. doi: 10.1002/cncy.20016.